Faculty profile

William Chu

Back to faculty

Assistant ProfessorDepartment of Radiation OncologyUniversity of Toronto

William Chu

Assistant Professor

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
23 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,995

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney
International Journal of Radiation Oncology Biology Physics · 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.
JAMA network open · 2026
Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.
International journal of radiation oncology, biology, physics · 2026

All 71 publications

71 publications.

Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney

Ali M, Correa RJM, Pryor D, Higgs B, Sridharan S, Sidhom M, Muacevic A, Onishi H, Swaminath A, Grubb W

International Journal of Radiation Oncology Biology Physics20265 citations

DOI: 10.1016/j.ijrobp.2025.08.043

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Tseng CL, Vesprini D, Hudson JM, Ong WL, Kennedy T, Helou J, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

JAMA network open20262 citationsOpen Access

DOI: 10.1001/jamanetworkopen.2026.0146 PMID: 41739470

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Ong WL, Davidson M, Wronski M, Kang T, Cheung P, Chu W, Chung H, Liu S, Morton G, Tseng CL, Vesprini D, Zhang L, Poon C, Loblaw A

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.08.014 PMID: 40819809

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Ong WL, Kennedy T, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

European urology oncology20259 citationsOpen Access

DOI: 10.1016/j.euo.2024.12.015 PMID: 39904690

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.

Ong WL, Quon H, Ong A, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Alayed Y, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Kulasingham-Poon M, Mamedov A, Deabreu A, Loblaw A

European urology oncology20253 citationsOpen Access

DOI: 10.1016/j.euo.2025.03.011 PMID: 40288917

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials.

Kennedy TAC, Ong WL, Quon H, Cheung P, Chu W, Chung H, Vesprini D, Panjwani D, Alayed Y, Pang G, Korol R, Zhang L, Mamedov A, Deabreu A, Loblaw A

International journal of radiation oncology, biology, physics2025

DOI: 10.1016/j.ijrobp.2024.09.009 PMID: 39293531

Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney

Tan VS, Correa RJM, Warner A, Ali M, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A

European Urology Oncology202413 citations

DOI: 10.1016/j.euo.2024.06.012

Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma

Schep DG, Vansantvoort J, Dayes I, Lukka H, Quan K, Kapoor A, Chow T, Chu W, Swaminath A

International Journal of Radiation Oncology Biology Physics20249 citations

DOI: 10.1016/j.ijrobp.2023.12.005

Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).

Glicksman RM, Loblaw A, Morton G, Vesprini D, Szumacher E, Chung HT, Chu W, Liu SK, Tseng CL, Correa R, Deabreu A, Mamedov A, Zhang L, Cheung P

International journal of radiation oncology, biology, physics20247 citations

DOI: 10.1016/j.ijrobp.2023.11.006 PMID: 37979707

Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials.

Glicksman RM, Loblaw A, Morton G, Vesprini D, Szumacher E, Chung HT, Chu W, Liu SK, Tseng CL, Davidson M, Deabreu A, Mamedov A, Zhang L, Cheung P

Clinical and translational radiation oncology20245 citationsOpen Access

DOI: 10.1016/j.ctro.2024.100843 PMID: 39318680

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

William Chu

Research

Latest papers

Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials.

Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney

Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma

Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).

Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials.

Frequent collaborators

Patrick Cheung

Andrew Loblaw

Danny Vesprini

Hans Chung

Stanley Liu

Gerard Morton

Chia-Lin Tseng

Arjun Sahgal

Ewa Szumacher

Anand Swaminath

Darby Erler

Hany Soliman

Merrylee McGuffin

Renee Korol

Ian Poon

Edward Chow

Geordi Pang

Jay Detsky

Laura D'Alimonte

Kelvin Chan

Scott Morgan

Sten Myrehaug

Yee Ung

Shun Wong

Gregory Czarnota

Drew Brotherston

Boyd McCurdy

Lee Chin

Linda Probyn

Kullervo Hynynen

Yoo-Joung Ko

Amandeep Taggar

Brian Keller

Simron Singh

Douglas Loblaw

Carlo DeAngelis

Julie Hallet

Samuel Pichardo

Nafisha Lalani

Olexandra Koshkina